NASDAQ · INBX
Inhibrx Biosciences Inc.
$69.65-$4.00 (-5.43%)
Inhibrx Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.19% below the high.
Loading market information…
NASDAQ · CBLI · USD
Stock price, earnings
Quote as of Sep 1, 2021, 04:00 AM UTC. Cached market data; not a live quote.
Price history is currently unavailable.
Cytocom, Inc.’s quoted price sits in the lower half of its reported 52-week range, 9.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cytocom, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$69.65-$4.00 (-5.43%)
Inhibrx Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.19% below the high.
$10.17-$0.19 (-1.82%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.36% below the high.
$5.38-$0.01 (-0.09%)
Third Harmonic Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.42% below the high.
$8.54-$0.64 (-6.97%)
Catabasis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 7.27% below the high.
$2.27$0.00 (0.0%)
Acelyrin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$15.15+$0.02 (+0.1%)
Merrimack Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.69% below the high.
$4.47$0.00 (0.0%)
CARGO Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 82.44% below the high.
$1.03-$0.01 (-0.49%)
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
